Efeito dos ácidos graxos n-3 e n-6 na expressão de genes do metabolismo de lipídeos e risco de aterosclerose
Palabras clave:
Ácidos graxos insaturados, Ácidos graxos ômega-3, Ácidos graxos ômega-6, Metabolismo lipídeos, Receptores ativados por proliferadores de peroxissomosResumen
A aterosclerose, principal responsável pela patogênese do infarto miocárdico e cerebral, bem como pela gangrena e por outras doenças vasculares periféricas, permanece como principal causa de morbidade e mortalidade nas populações “ocidentalizadas”. Estima-se que 17,5 milhões de pessoas morreram por doenças cardiovasculares em 2005, o que representou 30% das causas de morte nesse ano, e que, em 2015, 20 milhões de pessoas morrerão por doenças cardiovasculares no mundo. Os ácidos graxos n-3, principalmente os de cadeia longa, encontrados nos peixes, têm-se mostrado particularmente úteis na prevenção e tratamento de doenças como dislipidemias, diabetes mellitus e obesidade, apresentando importante efeito cardioprotetor. Nesse contexto, pesquisas têm evidenciado que ao menos parte dos benefícios dos ácidos graxos eicosapentaenóico e docosahexaenóico sobre o risco de doenças cardiovasculares é decorrente da modulação de genes responsivos aos receptores ativados por proliferadores de peroxissomos e envolvidos no metabolismo lipídico. Nesta revisão, pretende-se expor alguns mecanismos de ação dos ácidos graxos n-3 e n-6 sobre o metabolismo de lipídeos e de lipoproteínas. Conclui-se que muitos aspectos que contribuem para o risco de doenças cardiovasculares são afetados pela ingestão de n-3. Além da redução de triglicérides, fatores como o aumento de adiponectina, a redução da concentração de colesterol plasmático e a melhora do transporte reverso de colesterol também são responsáveis pela redução do risco de aterosclerose promovida pelos ácidos graxos n-3. No entanto, ainda são necessários estudos adicionais para definir mais claramente os mecanismos celulares e moleculares responsáveis pelo efeito cardioprotetor dos ácidos graxos n-3.
Citas
World Health Organization. Cardiovascular diseases. [cited 2007 Oct]. Available from: <http://www.who.int/cardiovascular_diseases/en/>.
Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease: fishing for a natural treatment. BMJ. 2004; 328(7430):30-5.
Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006; 296(15):1885-99.
Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990. Nature. 1993; 362(6423): 801-9.
Fan J, Watanabe T. Immflamatory reactions in the pathogeneses of atherosclerosis. J Atheros Thromb. 2003; 10(2):63-71.
Rodriguez-Cruz M, Tovar AR, Del Prado M, Torres N. Mecanismos moleculares de accion de los ácidos grasos poliinsaturados y SUS benefícios em la salud. Rev Invest Clin. 2005; 57(3):457-72.
Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients). Washington: National Academy Press; 2005. p.422-541.
Whelan J, Rust C. Innovative dietary sources of n3 fatty acids. Annu Rev Nutr. 2006; 26:75-103.
United States Department of Agriculture. National nutrient database for standard reference, release 19. [cited 2006]. Available from: <http://www.nal.usda.gov/fnic/foodcomp/search/>.
Burdge GC. Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot Essent Fatty Acids. 2006; 75(3):161-8.
McKenney JM, Sica D. Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health-Syst Pharm. 2007; 64(6):595-605.
Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr. 2000; 71(Suppl): 171S-5S.
Storlien LH, Hulbert AJ, Else PL. Polyunsaturated fatty acids, membrane function and metabolic diseases such as diabetes and obesity. Curr Opin Clin Nutr Metab Care. 1998; 1(6):559-63.
Chan EJ, Cho L. What can we expect from omega3 fatty acids? Cleve Clin J Med. 2009; 76(4):245-51.
American Heart Association. Fish and omega-3 fatty acids. [cited 2009 Mar. 3]. Available from: .
Ohman M, Akerfeldt T, Nilsson I, Rosen C, Hansson LO, Carlsson M, et al. Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acids. Ups J Med Sci. 2008; 113(3):315-23.
Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev. 2004; 62(9):333-9.
Staels B, Schoonjans K, Fruchart JC, Auwerx J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs). Biochimie. 1997; 79(2-3):95-9.
Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997; 8(3):159-66.
Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999; 10(3):245-57.
Michalik L, Wahli W. Peroxisome proliferatoractivated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol. 1999; 10(6): 564-70.
Lefebvre AM, Peinado-Onsurbe J, Leitersdorf I, Briggs MR, Paterniti JR, Fruchart JC, et al. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol. 1997; 17(9):1756-64.
Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature. 1996; 384(6604): 39-43.
Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest. 2000; 105(3):287-92.
Sampath H , Ntambi JM . Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu Rev Nutr. 2005; 25:317-40.
Schoonjans K, Staels B, Auwerx J. The Peroxisome proliferator-activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996; 1302(2): 93-109.
Food and Drug Administration. Consumer drug information sheet. [cited 2007 Jul 5]. Available from: <http://www.fda.gov/cder/consumerinfo/druginfo/omacor.htm>.
Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. IV Diretriz Brasileira Sobre Dislipidemias e Prevenção da Aterosclerose. Arq Bras Cardiol. 2007; 88(Supl 1):1-19.
Barter P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008; 102(8):1040-5. 30. Meyer BJ, Hammervold T, Rustan AC, Howe PR. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids. 2007; 42 (2): 109-15.
Goumas GS. Is there evidence-based hypolipidemic treatment with clinical benefit beyond statins? Angiology. 2009; 60(1):93-8.
Lewis SJ. Prevention and treatment of atherosclerosis: a practitioner’s guide for 2008. Am J Med. 2009; 122(1 Suppl):S38-50
Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369(9567):1090-8.
Chan DC, Watts GF, Nguyen MN, Barrett PHR. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 2006; 84(1): 37-43.
Zampolli A, Bysted A, Leth T, Mortensen A, De Caterina R, Falk E. Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis. 2006; 184(1):78-85.
Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, et al. Fish Oil Regulates Adiponectin Secretion by a Peroxisome Proliferator -Activated Receptor- γ-Dependent Mechanism in Mice. Diabetes. 2006; 55 (4):924-8.
Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105(24):2893-8.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7(8):941-6.
Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients. Arterioscler Thromb Vasc Biol. 2000; 20(6):1595-9.
Paschos GK, Zampelas A, Panagiotakos DB, Katsiougiannis S, Griffin BA, Votteas V, et al. Effects of flaxseed oil supplementation on plasma adiponectin levels in dyslipidemic men. Eur J Nutr. 2007; 46(6): 315-320.
Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, Hensler M, et al. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia. 2006; 49(2):394-7.
Bueno AA, Oyama LM, Oliveira C, Pisani LP, Ribeiro EB, Silveira VL, et al. Effects of different fatty acids and dietary lipids on adiponectin gene expression in 3T3-L1 cells and C57BL/6J mice adipose tissue. Pflugers Arch. 2008; 455(4):701-9.
Yu-Poth S, Yin D, Kris-Etherton PM, Zhao G, Etherton TD. Long-chain polyunsaturated fatty acids upregulate LDL receptor protein expression in fibroblasts and HepG2 cells. J Nutr. 2005; 135(11): 2541-5.
Ide T. Interaction of fish oil and conjugated linoleic acid in affecting hepatic activity of lipogenic enzymes and gene expression in liver and adipose tissue. Diabetes. 2005; 54(2):412-23.
Yanagita T, Wang YM, Nagao K, Ujino Y, Inoue N. Conjugated linoleic acid-induced fatty liver can be attenuated by combination with docosahexaenoic acid in C57BL/6N mice. J Agric Food Chem. 2005; 53(24):9629-33.
Ordovas JM. Genetic interactions with diet influence the risk of cardiovasculardisease. Am J Clin Nutr. 2006; 83(Suppl):443S-6S.
Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004; 350(1):29-37.
Dallongeville J, Baugé E, Tailleux A, Peters JM, Gonzalez FJ, Fruchart JC, et al. Peroxisome proliferator-activated receptor alpha is not ratelimiting for the lipoprotein-lowering action of fish oil. J Biol Chem. 2001; 276(7):4634-9.
Berthou L, Duverger N, Emmanuel F, Langouët S, Auwerx J, Guillouzo A, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest. 1996; 97(11):2408-16.
Spady DK, Kearney DM, Hobbs HH. Polyunsaturated fatty acids up-regulate hepatic scavenger receptor B1 (SR-BI) expression and HDL cholesteryl ester uptake in the hamster. J Lipid Res. 1999; 40(8):1384-94.
Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SRBI as a high density lipoprotein receptor. Science. 1996; 271(5248):518-20.
Le Morvan V, Dumon MF, Palos-Pinto A, Bérard AM. n-3 FA Increase Liver Uptake of HDL-Cholesterol in Mice. Lipids. 2002; 37(8):767-72.
Shefer S, Hauser S, Bekersky I, Mosbach EH. Biochemical site of regulation of bile acid biosynthesis in the rat. J Lipid Res. 1970; 11(5):404-11.
Bérard AM, Dumon MF, Darmon M. Dietary fish oil up-regulates cholesterol 7alpha-hydroxylase mRNA in mouse liver leading to an increase in bile acid and cholesterol excretion. FEBS Lett. 2004; 559(1-3): 125-8.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Helena Fonseca RAPOSO
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
